Literature DB >> 21116238

Optimizing dose-dense regimens for early-stage breast cancer.

Patrick G Morris, Clifford A Hudis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21116238     DOI： 10.1038/nrclinonc.2010.188

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  10 in total

1.  Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study.

Authors:  Volker Moebus; Christian Jackisch; Hans-Joachim Lueck; Andreas du Bois; Christoph Thomssen; Christian Kurbacher; Walther Kuhn; Ulrike Nitz; Andreas Schneeweiss; Jens Huober; Nadia Harbeck; Gunter von Minckwitz; Ingo B Runnebaum; Axel Hinke; Rolf Kreienberg; Gottfried E Konecny; Michael Untch
Journal:  J Clin Oncol       Date:  2010-05-10       Impact factor: 44.544

2.  Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea.

Authors:  Chau Dang; Nancy Lin; Beverly Moy; Steven Come; Steven Sugarman; Patrick Morris; Alyson Abbruzzi; Carol Chen; Richard Steingart; Sujata Patil; Larry Norton; Eric Winer; Clifford Hudis
Journal:  J Clin Oncol       Date:  2010-05-17       Impact factor: 44.544

3.  Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B.

Authors:  D R Budman; D A Berry; C T Cirrincione; I C Henderson; W C Wood; R B Weiss; C R Ferree; H B Muss; M R Green; L Norton; E Frei
Journal:  J Natl Cancer Inst       Date:  1998-08-19       Impact factor: 13.506

4.  A Gompertzian model of human breast cancer growth.

Authors:  L Norton
Journal:  Cancer Res       Date:  1988-12-15       Impact factor: 12.701

5.  Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.

Authors:  Marc L Citron; Donald A Berry; Constance Cirrincione; Clifford Hudis; Eric P Winer; William J Gradishar; Nancy E Davidson; Silvana Martino; Robert Livingston; James N Ingle; Edith A Perez; John Carpenter; David Hurd; James F Holland; Barbara L Smith; Carolyn I Sartor; Eleanor H Leung; Jeffrey Abrams; Richard L Schilsky; Hyman B Muss; Larry Norton
Journal:  J Clin Oncol       Date:  2003-02-13       Impact factor: 44.544

6.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.

Authors: 
Journal:  Lancet       Date:  2005 May 14-20       Impact factor: 79.321

7.  Combination chemotherapy as an adjuvant treatment in operable breast cancer.

Authors:  G Bonadonna; E Brusamolino; P Valagussa; A Rossi; L Brugnatelli; C Brambilla; M De Lena; G Tancini; E Bajetta; R Musumeci; U Veronesi
Journal:  N Engl J Med       Date:  1976-02-19       Impact factor: 91.245

8.  Dose-dense adjuvant Doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fraction.

Authors:  Patrick G Morris; Maura Dickler; Heather L McArthur; Tiffany Traina; Steven Sugarman; Nancy Lin; Beverly Moy; Steven Come; Laura Godfrey; Benjamin Nulsen; Carol Chen; Richard Steingart; Hope Rugo; Larry Norton; Eric Winer; Clifford A Hudis; Chau T Dang
Journal:  J Clin Oncol       Date:  2009-11-09       Impact factor: 44.544

9.  Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials.

Authors:  Michele De Laurentiis; Giuseppe Cancello; Diego D'Agostino; Mario Giuliano; Antonio Giordano; Emilia Montagna; Rossella Lauria; Valeria Forestieri; Angela Esposito; Lucrezia Silvestro; Roberta Pennacchio; Carmen Criscitiello; Agnese Montanino; Gennaro Limite; Angelo Raffaele Bianco; Sabino De Placido
Journal:  J Clin Oncol       Date:  2008-01-01       Impact factor: 44.544

10.  Weekly paclitaxel in the adjuvant treatment of breast cancer.

Authors:  Joseph A Sparano; Molin Wang; Silvana Martino; Vicky Jones; Edith A Perez; Tom Saphner; Antonio C Wolff; George W Sledge; William C Wood; Nancy E Davidson
Journal:  N Engl J Med       Date:  2008-04-17       Impact factor: 91.245
  10 in total
  3 in total

1.  Nanometronomic treatment of 4T1 breast cancer with nanocaged doxorubicin prevents drug resistance and circumvents cardiotoxicity.

Authors:  Serena Mazzucchelli; Michela Bellini; Luisa Fiandra; Marta Truffi; Maria A Rizzuto; Luca Sorrentino; Erika Longhi; Manuela Nebuloni; Davide Prosperi; Fabio Corsi
Journal:  Oncotarget       Date:  2017-01-31

2.  The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer--a systematic review.

Authors:  Diogo Mendes; Carlos Alves; Noémia Afonso; Fátima Cardoso; José Luís Passos-Coelho; Luís Costa; Sofia Andrade; Francisco Batel-Marques
Journal:  Breast Cancer Res       Date:  2015-11-17       Impact factor: 6.466

3.  Synergistic Targeting HER2 and EGFR with Bivalent Aptamer-siRNA Chimera Efficiently Inhibits HER2-Positive Tumor Growth.

Authors:  Lu Xue; Nita J Maihle; Xiaolin Yu; Shou-Ching Tang; Hong Yan Liu
Journal:  Mol Pharm       Date:  2018-10-01       Impact factor: 4.939
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.